The Food and Drug Administration yesterday issued the first emergency use authorization for a monkeypox diagnostic test, which is limited to laboratories designated by Quest Diagnostics that are certified under the Clinical Laboratory Improvement Amendments to perform high complexity tests. FDA also issued guidance on its EUA review priorities for monkeypox diagnostic tests.
 
The National Institutes of Health yesterday announced a 15-month clinical trial that will assess the effectiveness and safety of administering the JYNNEOS monkeypox vaccine intradermally. To stretch available supply of the vaccine, the Food and Drug Administration last month authorized health care providers to administer the vaccine intradermally to adults.

Related News Articles

Headline
The World Health Organization today recommended a new name for monkeypox that is intended to mitigate a rise in related racist and stigmatizing language…
Headline
The Department of Health and Human Services today renewed the nation’s monkeypox public health emergency declaration for another 90 days. When the PHE was…
Headline
As the monkeypox outbreak slows in the U.S., a new report from the Centers for Disease Control and Prevention highlights devastating outcomes of monkeypox for…
Headline
The Centers for Disease Control and Prevention today reported the first U.S. monkeypox case in a health care worker since the outbreak began in May. The report…
Headline
The Food and Drug Administration Friday authorized for emergency use the first commercial test kit to detect monkeypox in lesion swab specimens. Only…
Headline
Health and Human Services Secretary Xavier Becerra last week extended for 10 years his Aug. 4 public health emergency for monkeypox under the Public Readiness…